首页> 外文OA文献 >Synthesis of Polymeric Nanoparticles for the Controlled Release of Hydrophobic and Hydrophillic Theraputic Compounds
【2h】

Synthesis of Polymeric Nanoparticles for the Controlled Release of Hydrophobic and Hydrophillic Theraputic Compounds

机译:聚合物纳米粒子的合成,以控制释放疏水性和亲水性治疗化合物

摘要

Polymeric nanoparticle (NP) drug carriers present a promising technology for controlled release since they are capable of improving the encapsulation efficiency and stability of the drugs inside the NPs and also able to provide effective drug levels over a longer period of time, compared to traditional therapy. However, before the NP drug delivery technology becomes a reality, important parameters of NPs like size, drug loading ability and sustained release kinetics must be well investigated and optimized in order to minimize the adverse effects of chemotherapeutic compounds and prolong the drug releasing profile in a controlled manner. In order to accomplish this objective, this thesis proposed two novel methods for synthesis of NPs as drug delivery carriers, with assistance from bulk and microfluidic technologies, for hydrophobic and hydrophilic drugs, individually.For encapsulation of hydrophobic drugs, a modified flow focusing method was developed on a glass capillary microfluidic platform. Unlike conventional microfluidic flow focusing using two miscible phases, an insoluble component (DCM) was introduced into the dispersed phase to form a partially water-miscible precursor, and a transformation phenomenon of “jet—micro droplets--nanoparticles” was firstly observed instead of the “jet—micro droplets” or “jet—nanoparticles” from traditional flow focusing. Using Doxorubicin as a drug model, size-tunable Doxorubicin-PLGA NPs (80~170 nm) were synthesized by adjusting the flow rates, polymer concentration and the volume fraction of DCM in dispersed phase with an excellent monodispersity (PDI=0.1~0.2) which was superior to those from conventional flow focusing. We also found that drug loading content increased when volume ratio of DCM/DMSO in dispersed phase increased, with a considerable mass loading ratio up to 26.3%. In addition, Doxorubicin-PLGA NPs synthesized with DCM/DMSO precursor exhibited a slower drug release profile than those synthesized with pure DMSO precursor. This modified flow focusing method can also be extended to encapsulate inorganic compounds, such as iron oxide (Fe2O3) for a combination of chemotherapy and thermo-therapy, and showed a better loading ability of Fe2O3 than conventional research using pure DMSO. This method successfully combined the advantages from previous classical drug encapsulation techniques: small particle size, ease to operation—like nanoprecipitation; monodispersity, high drug encapsulation efficiency—like emulsion-based methods, provided us a promising tool for preparing nanoparticle carriers for multiple drug loading of both organic drugs and inorganic compoundsFor encapsulation and release of hydrophilic drugs, a modified bulk drop-wise nanoprecipiation method was designed by separating drug and polymer into aqueous and DMSO phases, respectively. In this case, we successfully solved the problem of the poor solubility of hydrophilic drug in organic solvents, for which reason the traditional nanoprecipitation method was limited to the application of hydrophilic drug encapsulation. Monodisperse ciprofloxacin-loaded PLA (poly (D,L-lactide))-Dextran and PLGA-PEG (poly (lactide-co-glycolide)-block-poly (ethylene glycol)) NPs were prepared of a tunable size range (80~200 nm). The drug loading ability, up to 18.6% (w/w), was found having an excellent linear correlation with the original feed of the ciprofloxacin drug, which indicated that drug content encapsulated by the NPs could be precisely controlled and an in-vitro sustained release was achieved up to 95.4% in 6 days.This thesis demonstrated the design and mechanism of different drug encapsulation and release systems; and synthesis, characterization, and optimization of drug-loaded polymeric nanoparticles. Our novel drug delivery systems significantly improved the encapsulation efficiency of various therapeutic compounds and exhibited a sustained-release profile. These nano-drug-delivery systems exploited intrinsic properties of NPs for controlled release, and will not only benefit the field of nanobiomedicine, but also could be further applied to food, flavor, fragrance and cosmetics industry.
机译:高分子纳米颗粒(NP)药物载体是控释技术的有希望的技术,因为与传统疗法相比,它们能够提高NP内药物的包封效率和稳定性,并且能够在更长的时间内提供有效的药物水平。但是,在NP药物递送技术成为现实之前,必须充分研究和优化NP的重要参数,例如大小,载药能力和持续释放动力学,以最大程度地减少化学治疗化合物的不利影响并延长药物释放曲线。控制方式。为了实现这一目标,本论文提出了两种新颖的合成NPs作为药物传递载体的方法,分别在本体和微流体技术的帮助下,分别用于疏水性和亲水性药物的制备。在玻璃毛细管微流体平台上开发。与使用两个可混溶相的常规微流体流动聚焦不同,将不溶性组分(DCM)引入分散相以形成部分可与水混溶的前体,并且首先观察到“喷射-微滴-纳米颗粒”的转化现象,而不是传统流聚焦技术中的“喷射微滴”或“喷射纳米颗粒”。以阿霉素为药物模型,通过调节分散相中的流速,聚合物浓度和DCM的体积分数,以优异的单分散性(PDI = 0.1〜0.2)合成大小可调的阿霉素-PLGA NPs(80〜170 nm)。优于传统的流聚焦技术。我们还发现,当分散相中DCM / DMSO的体积比增加时,药物负载量会增加,相当大的质量负载率可达26.3%。此外,用DCM / DMSO前体合成的阿霉素-PLGA NPs相比用纯DMSO前体合成的阿霉素-PLGA NPs的药物释放曲线要慢。这种改进的流聚焦方法还可以扩展为封装无机化合物,例如化学疗法和热疗法相结合的氧化铁(Fe2O3),并且与传统的纯DMSO研究相比,Fe2O3的负载能力更好。该方法成功地结合了以前的经典药物封装技术的优点:粒径小,易于操作-如纳米沉淀;单分散性,高药物封装效率(如基于乳液的方法),为我们提供了一种用于制备可同时装载多种有机药物和无机化合物的纳米颗粒载体的有前途的工具。对于亲水性药物的封装和释放,设计了一种改进的逐滴纳米沉淀法通过将药物和聚合物分别分离为水相和DMSO相。在这种情况下,我们成功地解决了亲水性药物在有机溶剂中溶解度差的问题,因此传统的纳米沉淀方法仅限于亲水性药物包封的应用。制备了大小可调(80〜 200 nm)。发现高达18.6%(w / w)的载药量与环丙沙星药物的原始进料具有极好的线性相关性,这表明可以精确控制NP封装的药物含量并在体外持续6天内达到了95.4%的释放率。本文证明了不同药物包封和释放系统的设计和机理。载药聚合物纳米颗粒的合成,表征和优化。我们的新型药物递送系统显着提高了各种治疗性化合物的包封效率,并展现了持续释放特性。这些纳米药物递送系统利用了NPs的内在特性进行控释,不仅有利于纳米生物医学领域,而且可以进一步应用于食品,香料,香料和化妆品行业。

著录项

  • 作者

    Xu Jiang;

  • 作者单位
  • 年度 2016
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号